Short Interest in PAVmed Inc. (NASDAQ:PAVM) Grows By 19.0%

PAVmed Inc. (NASDAQ:PAVM) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 293,400 shares, a growth of 19.0% from the August 15th total of 246,600 shares. Based on an average daily volume of 81,900 shares, the short-interest ratio is currently 3.6 days. Currently, 3.2% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reduced their price target on shares of PAVmed from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, September 10th.

PAVmed Trading Down 3.6 %

Shares of NASDAQ:PAVM traded down $0.06 during mid-day trading on Tuesday, hitting $1.71. 7,850 shares of the company traded hands, compared to its average volume of 70,708. The stock has a 50-day moving average price of $0.98 and a two-hundred day moving average price of $1.48. PAVmed has a 12-month low of $0.60 and a 12-month high of $5.70. The stock has a market cap of $17.76 million, a P/E ratio of -0.19 and a beta of 0.66.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million for the quarter. As a group, analysts expect that PAVmed will post -5.88 earnings per share for the current year.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.